Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd63-KH in Post-kala Azar Dermal Leishmaniasis
NCT03969134Phase 2Completed
- Sponsor
- University of York
- Start
- Apr 2020
- Primary completion
- Aug 2022
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ChAd63-KH in Post kala-azar dermal leishmaniasis (PKDL), sponsored by University of York. Started Apr 2020; status: completed.
02
Drugs
ChAd63-KH
03
Conditions
Post kala-azar dermal leishmaniasis (PKDL)
Beyond the preview
Go deeper on NCT03969134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969134.